6-(1,3-Dioxo-2,3-dihydro-1H-isoindol-2-yl)-N-(2,2,2-trichloro-1-hydroxyethyl)hexanamide

Catalog No. :
ACZPKO292
CAS No. :
1443664-77-4
Molecular Formula :
C16H17Cl3N2O4
Molecular Weight :
407.68

IUPAC Name:6-(1,3-dioxoisoindolin-2-yl)-N-(2,2,2-trichloro-1-hydroxyethyl)hexanamide

6-(1,3-Dioxo-2,3-dihydro-1H-isoindol-2-yl)-N-(2,2,2-trichloro-1-hydroxyethyl)hexanamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$93.00Login to see priceInquiryInquiry
100mg95%$130.00Login to see priceInquiryInquiry
250mg95%$178.00Login to see priceInquiryInquiry
1g95%$445.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name6-(1,3-Dioxo-2,3-dihydro-1H-isoindol-2-yl)-N-(2,2,2-trichloro-1-hydroxyethyl)hexanamide
IUPAC Name6-(1,3-dioxoisoindolin-2-yl)-N-(2,2,2-trichloro-1-hydroxyethyl)hexanamide
MDL No.-
Molecular FormulaC16H17Cl3N2O4
Molecular Weight407.68
SMILESO=C(NC(O)C(Cl)(Cl)Cl)CCCCCN(C(C1=C2C=CC=C1)=O)C2=O
InChI KeyLASDHCMLWTXBCD-UHFFFAOYSA-N
Synonym6-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-N-(2,2,2-trichloro-1-hydroxyethyl)hexanamide;2H-Isoindole-2-hexanamide, 1,3-dihydro-1,3-dioxo-N-(2,2,2-trichloro-1-hydroxyethyl)-
CAS No.1443664-77-4

Synthetic Route by SureRoute

1. ACZPKO292 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHWVX789 route compound structure diagram
    ACHWVX789594-65-0 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACZPKO292 route product structure diagram
    ACZPKO2921443664-77-4
Inquiry

2. ACZPKO292 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACNUDR270 route compound structure diagram
    ACNUDR2704443-26-9 In Stock
  4. Then
  5. ACZPKO292 route product structure diagram
    ACZPKO2921443664-77-4
Inquiry

Comments (0)